DGS Capital Management LLC Invests $235,000 in Organon & Co. (NYSE:OGN)

DGS Capital Management LLC purchased a new stake in Organon & Co. (NYSE:OGN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 15,730 shares of the company’s stock, valued at approximately $235,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Barclays PLC increased its stake in shares of Organon & Co. by 238.0% in the 3rd quarter. Barclays PLC now owns 119,483 shares of the company’s stock worth $2,285,000 after acquiring an additional 84,136 shares during the last quarter. Weiss Asset Management LP acquired a new stake in Organon & Co. during the third quarter worth about $32,966,000. Cerity Partners LLC raised its stake in Organon & Co. by 94.0% during the third quarter. Cerity Partners LLC now owns 667,340 shares of the company’s stock worth $12,766,000 after purchasing an additional 323,308 shares during the period. Foundry Partners LLC acquired a new position in Organon & Co. in the 3rd quarter valued at about $7,642,000. Finally, Beddow Capital Management Inc. grew its stake in shares of Organon & Co. by 38.8% in the 3rd quarter. Beddow Capital Management Inc. now owns 306,675 shares of the company’s stock valued at $5,867,000 after buying an additional 85,775 shares during the period. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Analyst Ratings Changes

Separately, TD Cowen raised shares of Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $21.33.

Organon & Co. Stock Down 2.7 %

Shares of NYSE:OGN opened at $15.97 on Friday. The company has a market capitalization of $4.11 billion, a price-to-earnings ratio of 3.17, a PEG ratio of 0.87 and a beta of 0.76. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The business has a 50-day moving average price of $15.36 and a 200 day moving average price of $18.08. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. Organon & Co.’s revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.78 earnings per share. Sell-side analysts expect that Organon & Co. will post 3.82 EPS for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th were given a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 7.01%. The ex-dividend date was Tuesday, November 12th. Organon & Co.’s payout ratio is 22.22%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.